What is TANKE BIOSCIENCES CORP's earnings per share (EPS)?

TANKE BIOSCIENCES CORP (TNBI) reported diluted earnings per share of -$0.02 for fiscal year 2012. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TANKE BIOSCIENCES (TNBI) Financials

TNBI OTC

Trailing 12 months to September 30, 2013

Revenue $23.0M -19.5% YoY

Net Income -$1.6M -164.1% YoY

EPS (Diluted) -$0.12 -160.0% YoY

Free Cash Flow -$6.1M -273.3% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2013, ended Sep 30, 2013 Reported Nov 14, 2013 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2013, filed Nov 14, 2013. Each column of the statement tables below links to the filing it was taken from.

TANKE BIOSCIENCES CORP (TNBI) reported $23.0M in revenue over the twelve months to Sep 30, 2013, down 19.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TNBI FY2012 2026-10-24

Revenue expanded, but cash generation broke down as higher overhead and financing costs kept reported profit near zero.

By FY2012, operating income recovered to $4.5M while net income remained a $210K loss, showing that operating recovery did not translate into bottom-line earnings. The gap sits alongside interest expense of $1.4M, which helps explain why the income statement improved less than operating performance.

Cash conversion reversed: operating cash flow moved from $4.4M in FY2010 to -$1.2M in FY2012. Free cash flow likewise moved from $4.3M to -$2.0M, so expansion required more cash than the business produced.

Current liabilities rose from $3.5M in FY2011 to $12.1M in FY2012, changing the funding profile toward near-term claims. That shift reduced the current ratio to 1.8x; debt-to-equity was 0.1x, pointing to near-term liabilities rather than heavy long-term borrowing.

Financial Health Signals

Financial health score not available

TANKE BIOSCIENCES CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Weak

3/9

TANKE BIOSCIENCES CORP passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Interest Coverage Adequate

3.13x

TANKE BIOSCIENCES CORP earns $3.13 in operating income for every $1 of interest expense ($4.5M vs $1.4M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$6.0M

YoY-39.0%

QoQ+8.3%

TANKE BIOSCIENCES CORP generated $6.0M in revenue in Q3 2013. This represents a decrease of 39.0% from the same quarter a year earlier. Against the prior quarter it is up 8.3%.

EBITDA

-$463K

YoY-121.1%

QoQ-329.3%

TANKE BIOSCIENCES CORP's EBITDA was -$463K in Q3 2013, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 121.1% from the same quarter a year earlier. Against the prior quarter it is down 329.3%.

Net Income

-$302K

YoY-131.2%

QoQ-355.6%

TANKE BIOSCIENCES CORP reported a net loss of $302K in Q3 2013. This represents a decrease of 131.2% from the same quarter a year earlier. Against the prior quarter it is down 355.6%.

EPS (Diluted)

-$0.02

YoY-128.6%

QoQ-300.0%

TANKE BIOSCIENCES CORP earned -$0.02 per diluted share (EPS) in Q3 2013. This represents a decrease of 128.6% from the same quarter a year earlier. Against the prior quarter it is down 300.0%.

Cash & Balance Sheet

Free Cash Flow

$538K

YoY-52.8%

QoQn/m

TANKE BIOSCIENCES CORP generated $538K in free cash flow in Q3 2013, representing cash available after capex. This represents a decrease of 52.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$5.1M

YoY-54.2%

QoQ+7.0%

TANKE BIOSCIENCES CORP held $5.1M in cash against $733K in long-term debt as of Q3 2013, with $12.2M of liabilities due within a year.

Shares Outstanding

13M

YoY0.0%

QoQ0.0%

TANKE BIOSCIENCES CORP had 13M shares outstanding in Q3 2013. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2013.

Margins & Returns

Gross Margin

28.0%

YoY-6.2pp

QoQ-4.7pp

TANKE BIOSCIENCES CORP's gross margin was 28.0% in Q3 2013, indicating the percentage of revenue retained after direct costs. This is down 6.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.7 percentage points.

Operating Margin

-8.8%

YoY-30.8pp

QoQ-11.5pp

TANKE BIOSCIENCES CORP's operating margin was -8.8% in Q3 2013, reflecting core business profitability. This is down 30.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.5 percentage points.

Net Margin

-5.0%

YoY-14.8pp

QoQ-7.1pp

TANKE BIOSCIENCES CORP's net profit margin was -5.0% in Q3 2013, showing the share of revenue converted to profit. This is down 14.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 7.1 percentage points.

Return on Equity

-1.9%

YoY-7.8pp

QoQ-2.7pp

TANKE BIOSCIENCES CORP's quarterly ROE was -1.9% in Q3 2013: one quarter's net income over shareholder equity, not annualized. This is down 7.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.7 percentage points.

Capital Allocation

Capital Expenditures

$1.1M

YoY+160.9%

QoQ+75.0%

TANKE BIOSCIENCES CORP invested $1.1M in capex in Q3 2013, funding long-term assets and infrastructure. This represents an increase of 160.9% from the same quarter a year earlier. Against the prior quarter it is up 75.0%.

R&D Spending

Not reported for Q3 2013.

Share Buybacks

Not reported for Q3 2013.

TNBI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TNBI quarterly income statement

Metric	TTM	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Revenue	$23.0M	$28.6M+19.8%	$23.8M+18.6%	$20.1M	N/A
Cost of Revenue	$15.5M	$18.6M+23.6%	$15.1M+18.6%	$12.7M	N/A
Gross Profit	$7.4M	$9.9M+13.4%	$8.8M+18.5%	$7.4M	N/A
R&D Expenses	N/A	$291K+18.1%	$246K	N/A	N/A
SG&A Expenses	$7.2M	$5.3M-24.4%	$7.0M+155.5%	$2.7M	N/A
Operating Income	-$57K	$4.5M+160.6%	$1.7M-60.2%	$4.4M	N/A
EBITDA	N/A	$5.2M+141.6%	$2.1M-52.6%	$4.5M	N/A
Interest Expense	$595K	$1.4M+6.2%	$1.4M+1258.1%	$100K	N/A
Income Tax	$238K	$832K+22.1%	$681K+17.0%	$582K	N/A
Net Income	-$1.6M	-$210Kn/m	-$3.1M-214.5%	$2.7M+6.0%	$2.6M
EPS (Basic)	N/A	-$0.02n/m	-$0.24	$0.34	N/A
EPS (Diluted)	-$0.12	-$0.02n/m	-$0.24	$0.34	N/A
Diluted Shares (Avg)	N/A	N/A	13M	11M	N/A

Metric	Q3'1310-Q	Q2'1310-Q	Q1'1310-Q	Q4'1210-K	Q3'1210-Q	Q2'1210-Q	Q1'1210-Q	Q4'1110-K
Revenue	$6.0M-39.0%	$5.6M-25.0%	$4.7M+2.6%	$6.7M+0.4%	$9.9M+58.6%	$7.4M+48.9%	$4.5M-23.6%	$6.7M
Cost of Revenue	$4.3M-33.3%	$3.8M-20.0%	$3.0M+1.4%	$4.5M+2.9%	$6.5M+62.9%	$4.7M+45.8%	$3.0M-16.0%	$4.3M
Gross Profit	$1.7M-50.0%	$1.8M-33.5%	$1.7M+4.9%	$2.2M-4.1%	$3.4M+50.9%	$2.7M+54.7%	$1.6M-34.6%	$2.3M
SG&A Expenses	$2.2M+81.7%	$1.6M+31.9%	$1.6M+51.0%	$1.7M+25.9%	$1.2M+15.0%	$1.2M-12.2%	$1.1M-65.3%	$1.4M
Operating Income	-$530K-124.3%	$150K-90.0%	-$40K-108.2%	$363K-64.4%	$2.2M+81.3%	$1.5M+552.2%	$489Kn/m	$1.0M
EBITDA	-$463K-121.1%	$202K-86.6%	$140K-77.1%	$844K-37.6%	$2.2M+82.1%	$1.5M+438.1%	$612Kn/m	$1.4M
Interest Expense	-$47K-114.7%	$39K-89.3%	$215K-42.4%	$387Kn/m	$316K-61.1%	$369K-12.9%	$373K+43.8%	-$136K
Income Tax	-$27K-112.1%	$54K-82.9%	$32K-72.5%	$179K+1.7%	$223K+20.1%	$314K+193.1%	$117K-45.3%	$176K
Net Income	-$302K-131.2%	$118K-56.6%	-$676Kn/m	-$780K-139.2%	$969Kn/m	$272Kn/m	-$671Kn/m	$2.0M
EPS (Basic)	-$0.02-128.6%	$0.01-50.0%	-$0.05n/m	-$0.06-137.5%	$0.07n/m	$0.02n/m	-$0.05n/m	$0.16+45.5%
EPS (Diluted)	-$0.02-128.6%	$0.01-50.0%	-$0.05n/m	-$0.06-137.5%	$0.07n/m	$0.02n/m	-$0.05n/m	$0.16+45.5%
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	13M0.0%	13M0.0%	13M+9.5%	N/A

Not reported in any period shown, so not listed: R&D Expenses.

TNBI Balance Sheet

TNBI quarterly balance sheet

Metric	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Total Assets	$28.8M+15.9%	$24.9M+87.6%	$13.3M	N/A
Current Assets	$22.4M+18.3%	$18.9M+146.5%	$7.7M	N/A
Cash & Equivalents	$6.2M-19.9%	$7.7M+246.5%	$2.2M+22.2%	$1.8M
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0
Inventory	$1.4M+19.1%	$1.2M-12.3%	$1.4M	N/A
Accounts Receivable	$2.0M+3.6%	$1.9M+8.5%	$1.8M	N/A
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0
Total Liabilities	$12.9M+43.1%	$9.0M+208.0%	$2.9M	N/A
Current Liabilities	$12.1M+241.1%	$3.5M+47.4%	$2.4M	N/A
Non-Current Liabilities	$831K-84.9%	$5.5M+942.1%	$526K	N/A
Long-Term Debt	$793K+26.1%	$628K+38.7%	$453K	N/A
Total Equity	$15.8M-0.6%	$15.9M+94.2%	$8.2M+26.8%	$6.4M
Retained Earnings	$2.5M-7.8%	$2.7M-53.8%	$5.8M	N/A

Metric	Q3'1310-Q	Q2'1310-Q	Q1'1310-Q	Q4'1210-K	Q3'1210-Q	Q2'1210-Q	Q1'1210-Q	Q4'1110-K
Total Assets	$28.8M-0.1%	$29.5M+8.0%	$28.7M+17.2%	$28.8M+15.9%	$28.8M+9.2%	$27.3M+16.9%	$24.5M	$24.9M+87.6%
Current Assets	$19.7M-11.3%	$21.9M+6.1%	$21.7M+18.3%	$22.4M+18.3%	$22.2M+4.5%	$20.7M+11.0%	$18.4M	$18.9M+146.5%
Cash & Equivalents	$5.1M-54.2%	$4.7M-52.9%	$5.6M-26.9%	$6.2M-19.9%	$11.0M+8.1%	$10.0M-4.6%	$7.6M+28.3%	$7.7M+246.5%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Inventory	$1.6M+0.7%	$2.1M+65.7%	$1.4M+2.7%	$1.4M+19.1%	$1.6M+52.3%	$1.3M+3.8%	$1.4M	$1.2M-12.3%
Accounts Receivable	$2.8M+21.3%	$2.4M+31.3%	$1.8M+7.2%	$2.0M+3.6%	$2.3M-55.0%	$1.8M+6.4%	$1.7M	$1.9M+8.5%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m
Total Liabilities	$13.1M+6.4%	$13.6M+16.9%	$13.3M+45.0%	$12.9M+43.1%	$12.3M+2.1%	$11.6M+46.0%	$9.2M	$9.0M+208.0%
Current Liabilities	$12.2M+9.6%	$12.7M+30.0%	$11.8M+33.7%	$12.1M+241.1%	$11.2M+115.5%	$9.8M+241.6%	$8.8M	$3.5M+47.4%
Non-Current Liabilities	$863K-24.9%	$891K-51.9%	$1.5M+343.6%	$831K-84.9%	$1.1M-83.3%	$1.9M-63.7%	$335K	$5.5M+942.1%
Long-Term Debt	$733K-22.7%	$809K-49.1%	$1.4Mn/m	$793K+26.1%	$948K+0.4%	$1.6M+71.2%	$0	$628K+38.7%
Total Equity	$15.6M-5.9%	$15.7M+0.3%	$15.2M-0.6%	$15.8M-0.6%	$16.5M+15.1%	$15.7M+1.8%	$15.3M	$15.9M+94.2%
Retained Earnings	$1.6M-50.2%	$1.9M-16.1%	$1.8M-10.6%	$2.5M-7.8%	$3.3M+202.1%	$2.3M-5.1%	$2.0M	$2.7M-53.8%

Not reported in any period shown, so not listed: Goodwill.

TNBI Cash Flow Statement

TNBI quarterly cash flow statement

Metric	TTM	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Operating Cash Flow	-$3.6M	-$1.2M-132.4%	$3.7M-16.7%	$4.4M	N/A
Depreciation & Amortization	N/A	$636K+59.1%	$400K+193.8%	$136K	N/A
Stock-Based Compensation	N/A	N/A	$2.5Mn/m	$0	N/A
Capital Expenditures	$2.5M	$856K+22.2%	$701K+821.5%	$76K	N/A
Free Cash Flow	-$6.1M	-$2.0M-169.1%	$3.0M-31.5%	$4.3M	N/A
Investing Cash Flow	-$2.4M	-$1.5Mn/m	-$3.7Mn/m	-$2.8M	N/A
Financing Cash Flow	-$95K	$1.1M-80.7%	$5.8Mn/m	-$1.2M	N/A

Metric	Q3'1310-Q	Q2'1310-Q	Q1'1310-Q	Q4'1210-K	Q3'1210-Q	Q2'1210-Q	Q1'1210-Q	Q4'1110-K
Operating Cash Flow	$1.6M+3.8%	-$135K-107.6%	-$101K-119.9%	-$5.0M-785.6%	$1.6M+5889.2%	$1.8M-1.4%	$509K-53.9%	$731K-55.6%
Depreciation & Amortization	$67K+304.6%	$52K+253.9%	$180K+45.3%	$232K-15.4%	$17K+351.6%	$15K-71.3%	$124K+956.4%	$274K+296.2%
Stock-Based Compensation	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A
Capital Expenditures	$1.1M+160.9%	$613K+215.1%	$746K+285.3%	$56K-74.8%	$412K+9.3%	$195K+75.5%	$194K-8.3%	$224K+560.6%
Free Cash Flow	$538K-52.8%	-$748K-147.6%	-$847K-368.9%	-$5.1M-1100.2%	$1.1Mn/m	$1.6M-6.4%	$315K-64.7%	$507K-68.6%
Investing Cash Flow	-$1.1Mn/m	-$645Kn/m	-$746Kn/m	$114Kn/m	-$394Kn/m	-$866K-693.6%	-$380Kn/m	-$2.1Mn/m
Financing Cash Flow	-$241Kn/m	-$159K-111.4%	$230Kn/m	$76Kn/m	-$45Kn/m	$1.4M-49.9%	-$305K-108.7%	-$466Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

TNBI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TNBI quarterly financial ratios

Metric	FY1210-K	FY1110-K	FY1010-K	FY0910-K
Gross Margin	34.8%-2.0pp	36.8%0.0pp	36.8%	N/A
Operating Margin	15.9%+8.6pp	7.3%-14.5pp	21.8%	N/A
Net Margin	-0.7%+12.4pp	-13.2%-26.8pp	13.6%	N/A
Return on Equity	-1.3%+18.4pp	-19.8%-53.3pp	33.5%-6.6pp	40.2%
Return on Assets	-0.7%+11.9pp	-12.6%-33.2pp	20.6%	N/A
Current Ratio	1.85-3.5x	5.33+2.1x	3.19	N/A
Debt-to-Equity	0.050.0x	0.040.0x	0.06	N/A
Liabilities-to-Equity	0.82+0.3x	0.57+0.2x	0.36	N/A
Asset Turnover	0.990.0x	0.96-0.6x	1.51	N/A
FCF Margin	-7.1%-19.5pp	12.4%-9.1pp	21.4%	N/A

Metric	Q3'1310-Q	Q2'1310-Q	Q1'1310-Q	Q4'1210-K	Q3'1210-Q	Q2'1210-Q	Q1'1210-Q	Q4'1110-K
Gross Margin	28.0%-6.2pp	32.7%-4.2pp	35.8%+0.8pp	33.4%-1.6pp	34.2%-1.7pp	36.9%+1.4pp	35.0%-5.9pp	35.0%
Operating Margin	-8.8%-30.8pp	2.7%-17.5pp	-0.9%-11.6pp	5.4%-9.9pp	22.0%+2.8pp	20.2%+15.6pp	10.8%+22.8pp	15.3%
Net Margin	-5.0%-14.8pp	2.1%-1.6pp	-14.5%+0.3pp	-11.7%-41.6pp	9.8%+32.9pp	3.7%+36.8pp	-14.8%+19.3pp	29.9%
Return on Equity	-1.9%-7.8pp	0.8%-1.0pp	-4.5%-0.1pp	-5.0%-17.5pp	5.9%+15.9pp	1.7%+12.5pp	-4.4%	12.5%
Return on Assets	-1.1%-4.4pp	0.4%-0.6pp	-2.4%+0.4pp	-2.7%-10.7pp	3.4%+8.8pp	1.0%+8.1pp	-2.7%	8.0%
Current Ratio	1.61-0.4x	1.73-0.4x	1.84-0.2x	1.85-3.5x	1.99-2.1x	2.11-4.4x	2.08	5.33+2.1x
Debt-to-Equity	0.050.0x	0.050.0x	0.09+0.1x	0.050.0x	0.060.0x	0.100.0x	0.00	0.040.0x
Liabilities-to-Equity	0.84+0.1x	0.87+0.1x	0.87+0.3x	0.82+0.3x	0.74-0.1x	0.74+0.2x	0.60	0.57+0.2x
Asset Turnover	0.21-0.1x	0.19-0.1x	0.160.0x	0.230.0x	0.34+0.1x	0.27+0.1x	0.19	0.27
FCF Margin	8.9%-2.6pp	-13.4%-34.6pp	-18.2%-25.1pp	-75.8%-83.5pp	11.5%+17.1pp	21.2%-12.5pp	6.9%-8.1pp	7.6%

Where TANKE BIOSCIENCES CORP Ranks

Frequently Asked Questions

What is TANKE BIOSCIENCES CORP's annual revenue?

TANKE BIOSCIENCES CORP (TNBI) reported $28.6M in total revenue for fiscal year 2012. This represents a 19.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is TANKE BIOSCIENCES CORP's revenue growing?

TANKE BIOSCIENCES CORP (TNBI) revenue grew by 19.8% year-over-year, from $23.8M to $28.6M in fiscal year 2012.

Is TANKE BIOSCIENCES CORP profitable?

No, TANKE BIOSCIENCES CORP (TNBI) reported a net loss of $1.6M over the trailing 12 months to September 30, 2013. In fiscal year 2012 it reported a net loss of $210K, with a net profit margin of -0.7%.

What is TANKE BIOSCIENCES CORP's EBITDA?

TANKE BIOSCIENCES CORP (TNBI) had EBITDA of $5.2M in fiscal year 2012, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does TANKE BIOSCIENCES CORP have?

As of fiscal year 2012, TANKE BIOSCIENCES CORP (TNBI) had $6.2M in cash and equivalents against $793K in long-term debt.

What is TANKE BIOSCIENCES CORP's gross margin?

TANKE BIOSCIENCES CORP (TNBI) had a gross margin of 34.8% in fiscal year 2012, indicating the percentage of revenue retained after direct costs of goods sold.

What is TANKE BIOSCIENCES CORP's operating margin?

TANKE BIOSCIENCES CORP (TNBI) had an operating margin of 15.9% in fiscal year 2012, reflecting the profitability of core business operations before interest and taxes.

What is TANKE BIOSCIENCES CORP's net profit margin?

TANKE BIOSCIENCES CORP (TNBI) had a net profit margin of -0.7% in fiscal year 2012, representing the share of revenue converted into profit after all expenses.

What is TANKE BIOSCIENCES CORP's return on equity (ROE)?

TANKE BIOSCIENCES CORP (TNBI) has a return on equity of -1.3% for fiscal year 2012, measuring how efficiently the company generates profit from shareholder equity.

What is TANKE BIOSCIENCES CORP's free cash flow?

TANKE BIOSCIENCES CORP (TNBI) recorded an outflow of $2.0M in free cash flow during fiscal year 2012. This represents a -169.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TANKE BIOSCIENCES CORP's operating cash flow?

TANKE BIOSCIENCES CORP (TNBI) recorded an outflow of $1.2M in operating cash flow during fiscal year 2012, representing cash used by core business activities.

What are TANKE BIOSCIENCES CORP's total assets?

TANKE BIOSCIENCES CORP (TNBI) had $28.8M in total assets as of fiscal year 2012, including both current and long-term assets.

What are TANKE BIOSCIENCES CORP's capital expenditures?

TANKE BIOSCIENCES CORP (TNBI) invested $856K in capital expenditures during fiscal year 2012, funding long-term assets and infrastructure.

How much does TANKE BIOSCIENCES CORP spend on research and development?

TANKE BIOSCIENCES CORP (TNBI) invested $291K in research and development during fiscal year 2012.

How many shares does TANKE BIOSCIENCES CORP have outstanding?

TANKE BIOSCIENCES CORP (TNBI) had 13M shares outstanding as of fiscal year 2012.

What is TANKE BIOSCIENCES CORP's current ratio?

TANKE BIOSCIENCES CORP (TNBI) had a current ratio of 1.85 as of fiscal year 2012, which is generally considered healthy.

What is TANKE BIOSCIENCES CORP's debt-to-equity ratio?

TANKE BIOSCIENCES CORP (TNBI) had a debt-to-equity ratio of 0.05 as of fiscal year 2012. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is TANKE BIOSCIENCES CORP's liabilities-to-equity ratio?

TANKE BIOSCIENCES CORP (TNBI) had a liabilities-to-equity ratio of 0.82 as of fiscal year 2012, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is TANKE BIOSCIENCES CORP's return on assets (ROA)?

TANKE BIOSCIENCES CORP (TNBI) had a return on assets of -0.7% for fiscal year 2012, measuring how efficiently the company uses its assets to generate profit.

What is TANKE BIOSCIENCES CORP's Piotroski F-Score?

TANKE BIOSCIENCES CORP (TNBI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can TANKE BIOSCIENCES CORP cover its interest payments?

TANKE BIOSCIENCES CORP (TNBI) has an interest coverage ratio of 3.13x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.